Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649790 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 277
- Enrollment target
NCT02649790: Completed Phase 1 study, sponsored by Karyopharm Therapeutics.
NCT02649790 is a Phase 1 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 277 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (362% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649790, a Phase 1 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 277 participants
- Enrollment target
Study Summary
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
Interventions
- DRUG Dexamethasone
- DRUG ASTX727
- DRUG KPT-8602
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-01 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 1 |
What the finished NCT02649790 record still lists
NCT02649790 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (362% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02649790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02649790 about?
NCT02649790 is a clinical study titled "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications". This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple my...
What is the current status of trial NCT02649790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 277 participants. The study started on 2016-01. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT02649790?
The interventions under investigation include: Dexamethasone (DRUG), ASTX727 (DRUG), KPT-8602 (DRUG).
Who is sponsoring clinical trial NCT02649790?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02649790's enrollment target sits among peer trials
277 147th of 2000 higher than 1,853 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia